Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract HRS-7535 is an orally active small-molecule glucagon-like peptide-1 receptor agonist that showed weight-loss potential in a phase 1 study. In this completed multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 29 centers in China, we evaluated the efficacy and safety of HRS-7535 in adults with obesity without diabetes.
1Department of Endocrinology, The First Medical Center of People's Liberation Army General Hospital, Beijing, China 2Department of Endocrinology, Central Hospital of Dalian University of Technology, Dalian, Liaoning, China 3Department of Neurology, Johns Hopkins Hospital, Baltimore, MD, United States 4Yidu Cloud Technology Inc., Beijing, China 5School of Software Technology, Dalian University of Technology, Dalian, Liaoning, China Background: Accurately predicting intraoperative hemodynamic...
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
